Scarica l'app Stockscreener
58.75
3.04%
-1.84
Dopo l'orario di chiusura:
58.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Squarepoint Ops LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at Morgan Stanley global healthcare investor conference - Bitget
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen - StreetInsider
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Royalty Pharma PLC (RPRX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Position Increased by TD Waterhouse Canada Inc. - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Navigating Growth with a 16.5% Revenue Surge - DirectorsTalk Interviews
Royalty Pharma Updates on Novartis' HORIZON Trial Results - Intellectia AI
Royalty Pharma expects modest return despite pelacarsen trial failure - Investing.com
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - Quiver Quantitative
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - pmg-ky3.com
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - GlobeNewswire Inc.
Royalty Pharma Slides as Higher-Rate Jitters Seem to Outweigh Recent Strong Results - Quiver Quantitative
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma - Seeking Alpha
Royalty Pharma stock hits all-time high at 62.48 USD By Investing.com - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $7.84 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - MarketBeat
Royalty Pharma stock hits all-time high at 62.48 USD - Investing.com
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 6.41% Potential Upside - DirectorsTalk Interviews
Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX - MarketBeat
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Strong Buy Ratings and Promising Growth in the Biotech Sector - DirectorsTalk Interviews
Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal? - Sahm
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to "Strong-Buy" - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
RPHC5824520 Bond Profile — Key Metrics - TradingView
30,000 Shares in Royalty Pharma PLC $RPRX Purchased by Monetta Financial Services Inc. - MarketBeat
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity - Kalkine Media
Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma stock hits all-time high at 60.44 USD - Investing.com
Royalty Pharma stock hits all-time high at 60.44 USD By Investing.com - Investing.com Nigeria
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Commerzbank Aktiengesellschaft FI Invests $1.20 Million in Royalty Pharma PLC $RPRX - MarketBeat
How Investors Are Reacting To Royalty Pharma (RPRX) Buying Rusfertide Royalties From Zealand Pharma - simplywall.st
Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale - Stock Titan
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares - Investing.com South Africa
Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated - Stock Titan
Royalty Pharma (RPRX) CFO sells 11,002 shares in trading plan - Stock Titan
LYNWOOD PRICE CAPITAL MANAGEMENT LP's Royalty Pharma PLC(RPRX) Holding History - GuruFocus
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 10.49% Potential Upside - DirectorsTalk Interviews
S&CO Inc. Buys Shares of 358,302 Royalty Pharma PLC $RPRX - MarketBeat
Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years - Benzinga
Royalty Pharma (RPRX) Following Mixed Earnings Still Looks Close To Fair Value - Sahm
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):